GSK and RAPT Therapeutics
Type: Acquisition
Buyer: GSK plc
Seller: RAPT Therapeutics
Focus: Ozureprubart
Deal value: $2.2 billion
Financial impact: The acquisition of RAPT Therapeutics by GSK for approximately $2.2 billion ($58 per share), with about $1.9 billion net upfront investment, strengthens GSK’s immunology pipeline and provides long-term revenue potential through the development of the anti-IgE therapy ozureprubart for food allergies.
GSK completed the acquisition of RAPT Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, for approximately $2.2 billion following the deal announcement in January 2026. The transaction includes ozureprubart, a long-acting anti-IgE monoclonal antibody currently in Phase IIb development for the prevention of food allergies. Through the acquisition, GSK obtained global rights to the ozureprubart program, excluding Mainland China, Macau, Taiwan, and Hong Kong, and will also assume responsibility for milestone and royalty payments owed to Shanghai Jeyou Pharmaceutical Co.. The total cash consideration represents an equity value of about $2.2 billion, with GSK’s upfront investment estimated at around $1.9 billion after accounting for acquired cash.
Ozureprubart
Ozureprubart (RPT904/JYB1904) is a next-generation, long-acting anti-IgE monoclonal antibody developed by RAPT Therapeutics and originally discovered by Jemincare. It is designed to inhibit both free and cell-bound immunoglobulin E (IgE), a key driver of allergic diseases. It is being developed for conditions such as food allergies, asthma, chronic spontaneous urticaria, and other allergic disorders. The therapy, currently in Phase IIb clinical trials, aims to provide longer-lasting protection and less frequent dosing compared with existing anti-IgE treatments.
Market Impact of This Partnership
The acquisition of RAPT Therapeutics by GSK for approximately $2.2 billion, with a net upfront investment of about $1.9 billion, is expected to strengthen GSK’s position in the growing allergy and immunology therapeutics market. The deal provides GSK with global rights (excluding Mainland China, Hong Kong, Macau, and Taiwan) to ozureprubart, a long-acting anti-IgE monoclonal antibody currently in Phase IIb clinical trials for food allergies and other IgE-mediated diseases. By adding this next-generation therapy to its pipeline, GSK aims to expand its presence in high-value segments of allergic diseases and potentially capture significant future revenue if the drug successfully advances through clinical development and commercialisation.
“GSK’s $2.2 billion acquisition of RAPT Therapeutics strengthens its immunology pipeline and positions the company to capture future growth in the expanding food-allergy therapeutics market through the development of ozureprubart.”